AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25727055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical Exposure Therapy
Number of subjects: 138
Study 25727055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-submissive quadrant patients
Number of subjects: 138
Study 24332365 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical momentary assessment (GMA)
Number of subjects: 27
Study 22368260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing actinidine (sucked three times a day for six days)
Number of subjects: 14
Study 22368260 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets without actinidine
Number of subjects: 14
Study 20415152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra Coronary Shunt (ICS)
Number of subjects: 208
Study 20415152 — intervention group
Group type: COMPARATOR
Intervention: No Shunt
Number of subjects: 208
Study 17938383 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement of blood pressure
Number of subjects: 430
Study 15739120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 30‐45 mg/day
Number of subjects: 1880
Study 15739120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone + Metformin (PIO+MET)
Number of subjects: 1880
Study 15739120 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (GLIC) 80‐320 mg/day
Number of subjects: 1880
Study 15739120 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide + Metformin (GLIC+MET)
Number of subjects: 1880
Study 15739120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 1880
Study 15739120 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (GLIC)
Number of subjects: 1880
Study 12073296 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous sickle cell disease children
Number of subjects: 111
Study 12073296 — intervention group
Group type: COMPARATOR
Intervention: Normal control children
Number of subjects: 111
Study 9701155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Zn
Number of subjects: 205
Study 9701155 — intervention group
Group type: COMPARATOR
Intervention: 1 mg Zn
Number of subjects: 205
Study 9701155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 7832079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg once daily, SID group)
Number of subjects: 85
Study 7832079 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (300 mg in three divided doses, TID group)
Number of subjects: 85
Study 3049876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental) 1200 mg daily (400 mg t.i.d.)
Number of subjects: 35
Study 3049876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30938567 — intervention group
Group type: EXPERIMENTAL
Intervention: Language education intervention (LEI) comprising cognitive, adaptive and rational thinking training
Number of subjects: 86
Study 30938567 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 86
Study 29362960 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 56
Study 29362960 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 56
Study 29362960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Exercise (CE)
Number of subjects: 56
Study 29362960 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 27612501 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 169
Study 27612501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 27442397 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (1000 ml)
Number of subjects: 20
Study 27442397 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 20
Study 23294818 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CES device
Number of subjects: 0
Study 23294818 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0
Study 23294818 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 21250801 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (Days 1 or 2)
Number of subjects: 1001
Study 21250801 — intervention group
Group type: EXPERIMENTAL
Intervention: Late surgery (Days 7-14)
Number of subjects: 1001
Study 21250801 — intervention group
Group type: COMPARATOR
Intervention: Intermediate surgery (Days 3-6)
Number of subjects: 1001
Study 21250801 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (Days 1 or 2) for patients with hydrocephalus or Fisher Grade 3 or 4
Number of subjects: 1001
Study 18574578 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous nerve block (Group I)
Number of subjects: 40
Study 18574578 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injection (Group II)
Number of subjects: 40
Study 16861942 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (tac/MMF/steroids)
Number of subjects: 718
Study 16861942 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid stop
Number of subjects: 718
Study 16861942 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF stop
Number of subjects: 718
Study 12643964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of challenge-induced aversive emotional state
Number of subjects: 48
Study 12643964 — intervention group
Group type: COMPARATOR
Intervention: Observation of emotional response
Number of subjects: 48
Study 12643964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of bodily sensations
Number of subjects: 48
Study 11076430 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol gel 0.5% once daily
Number of subjects: 52
Study 11076430 — intervention group
Group type: COMPARATOR
Intervention: Timolol aqueous solution 0.5% twice daily
Number of subjects: 52
Study 9170340 — intervention group
Group type: EXPERIMENTAL
Intervention: N-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of NO-synthase
Number of subjects: 0
Study 9170340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9170340 — intervention group
Group type: EXPERIMENTAL
Intervention: N-monomethyl-L-arginine (L-NMMA)
Number of subjects: 0
Study 9170340 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 8067787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice based oral rehydration therapy (ORT)
Number of subjects: 52
Study 8067787 — intervention group
Group type: COMPARATOR
Intervention: WHO ORS
Number of subjects: 52
Study 8067787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice based ORT
Number of subjects: 52
Study 3287975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (single 2 g dose)
Number of subjects: 269
Study 3287975 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (multiple 2 g doses)
Number of subjects: 269
Study 31306216 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX203
Number of subjects: 28
Study 31306216 — intervention group
Group type: COMPARATOR
Intervention: IR CD-LD
Number of subjects: 28
Study 28549445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FC)
Number of subjects: 100
Study 28549445 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate (Cryo)
Number of subjects: 100
Study 24571126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300 (0.4 U/kg)
Number of subjects: 60
Study 24571126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300 (0.6 U/kg)
Number of subjects: 60
Study 24571126 — intervention group
Group type: COMPARATOR
Intervention: Gla-100 (0.4 U/kg)
Number of subjects: 60
Study 22474419 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on basal insulin therapy on top of oral agents
Number of subjects: 38
Study 22474419 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 20213516 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety item bank (15 items)
Number of subjects: 1529
Study 20213516 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms item bank (14 items)
Number of subjects: 1529
Study 20213516 — intervention group
Group type: EXPERIMENTAL
Intervention: Short forms and simulated computer adaptive tests
Number of subjects: 1529
Study 17634484 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 794
Study 17634484 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 794
Study 16086921 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose before IRA stenting followed by 75 mg daily)
Number of subjects: 133
Study 16086921 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (500 mg before IRA stenting followed by 250 mg twice daily)
Number of subjects: 133
Study 16086921 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 133
Study 16086921 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 133
Study 12126990 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (14 mg)
Number of subjects: 10
Study 12126990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg)
Number of subjects: 10
Study 12126990 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study 12126990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabstinent smoking
Number of subjects: 10
Study 12126990 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent smoking
Number of subjects: 10
Study 10102963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate 240 mg b.d. plus furazolidone 100 mg b.d. plus clarithromycin 250 mg b.d. (Group A)
Number of subjects: 180
Study 10102963 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg b.d. plus amoxycillin 1000 mg b.d. (Group B)
Number of subjects: 180
Study 10102963 — intervention group
Group type: COMPARATOR
Intervention: Furazolidone 100 mg b.d. plus josamycin 1000 mg b.d. (Group C)
Number of subjects: 180
Study 7521091 — intervention group
Group type: EXPERIMENTAL
Intervention: UroLume endoprosthesis
Number of subjects: 126
Study 2572793 — intervention group
Group type: EXPERIMENTAL
Intervention: NG monomethyl‐L‐arginine (L‐NMMA) infusion into the brachial arteries
Number of subjects: 0
Study 2572793 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine infusion
Number of subjects: 0
Study 2572793 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate infusion
Number of subjects: 0
Study 1089474 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomycin D (Act D) and Vincristine (Vcr) for 1 year after surgery and radiotherapy
Number of subjects: 0
Study 1089474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of Act D, Vcr, and cyclophosphamide
Number of subjects: 0
Study 1089474 — intervention group
Group type: COMPARATOR
Intervention: Four different drug combinations
Number of subjects: 0
Study 30664816 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (2 days/week for 45 minutes over 6 months)
Number of subjects: 135
Study 30664816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135
Study 28458129 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-selected song
Number of subjects: 12
Study 28458129 — intervention group
Group type: COMPARATOR
Intervention: White noise
Number of subjects: 12
Study 25421981 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 106
Study 25421981 — intervention group
Group type: COMPARATOR
Intervention: Intensified pharmacological treatment
Number of subjects: 106
Study 23171375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension group (N = 13)
Number of subjects: 22
Study 23171375 — intervention group
Group type: COMPARATOR
Intervention: Sleep maintenance group (N = 9)
Number of subjects: 22
Study 22093417 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (5-25 mg/d)
Number of subjects: 195
Study 22093417 — intervention group
Group type: COMPARATOR
Intervention: Tiapride (100-500 mg/d)
Number of subjects: 195
Study 22093417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 195
Study 19300989 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 2
Study 19300989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 2
Study 19300989 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 2
Study 17005086 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiweining (YWN) 200 ml, twice a day for 6 months
Number of subjects: 52
Study 17005086 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (GT) 2.5 mg, twice every week for 6 months
Number of subjects: 52
Study 17005086 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 52
Study 17005086 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiweining (YWN)
Number of subjects: 52
Study 17005086 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (GT)
Number of subjects: 52
Study 12775135 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg, once daily (FP200QD)
Number of subjects: 705
Study 12775135 — intervention group
Group type: COMPARATOR
Intervention: Montelukast 10 mg, once daily (MON10QD)
Number of subjects: 705
Study 12903451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-induced hypotension (MAP = 55 mmHg)
Number of subjects: 30
Study 12903451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-induced hypotension (MAP = 65 mmHg)
Number of subjects: 30
Study 12903451 — intervention group
Group type: COMPARATOR
Intervention: Normotension (Control group)
Number of subjects: 30
Study 9185464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (1‐3 mcg.kg‐1.min‐1)
Number of subjects: 52
Study 9185464 — intervention group
Group type: COMPARATOR
Intervention: Control (no preventive diltiazem)
Number of subjects: 52
Study 7952357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Healon)
Number of subjects: 0
Study 7952357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid of higher viscosity (Healon GV)
Number of subjects: 0
Study 3803417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox, 250 mg three times daily
Number of subjects: 52
Study 3803417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31541431 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax (single doses of 10–500 mg or two cycles of 30–600 mg or placebo once daily for 7 days followed by a 21-day washout)
Number of subjects: 73
Study 31541431 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing with lower doses of venetoclax (e.g., 150 mg daily)
Number of subjects: 73
Study 31541431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic dosing with higher doses (e.g., 400 mg 1 week on/3 weeks off)
Number of subjects: 73
Study 29752954 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 0
Study 29752954 — intervention group
Group type: COMPARATOR
Intervention: Complete fasting with placebo treatment
Number of subjects: 0
Study 29752954 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete fasting with leptin replacement
Number of subjects: 0
Study 29752954 — intervention group
Group type: COMPARATOR
Intervention: Leptin treatment vs placebo
Number of subjects: 0
Study 29752954 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment in women with HA
Number of subjects: 0
Study 27254034 — intervention group
Group type: EXPERIMENTAL
Intervention: YF vaccine with CYD‐TDV
Number of subjects: 787
Study 27254034 — intervention group
Group type: COMPARATOR
Intervention: YF vaccine with placebo
Number of subjects: 787
Study 27254034 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV after 2 injections
Number of subjects: 787
Study 27254034 — intervention group
Group type: COMPARATOR
Intervention: CYD‐TDV after 2 injections (placebo group)
Number of subjects: 787
Study 25083606 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE) with food antigens administered directly to the duodenal mucosa.
Number of subjects: 36
Study 25083606 — intervention group
Group type: COMPARATOR
Intervention: Control group (Barrett's esophagus patients) resumed their previous diet.
Number of subjects: 36
Study 22653459 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound packing after incision and drainage
Number of subjects: 57
Study 22653459 — intervention group
Group type: COMPARATOR
Intervention: No wound packing after incision and drainage
Number of subjects: 57
Study 22653459 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound packing
Number of subjects: 57
Study 22653459 — intervention group
Group type: COMPARATOR
Intervention: No wound packing
Number of subjects: 57
Study 19926749 — intervention group
Group type: EXPERIMENTAL
Intervention: Papanicolaou-based rapid stain
Number of subjects: 126
Study 19926749 — intervention group
Group type: COMPARATOR
Intervention: Wright-Giemsa-based rapid stain
Number of subjects: 126
Study 17891480 — intervention group
Group type: EXPERIMENTAL
Intervention: 250‐mg caffeine
Number of subjects: 48
Study 17891480 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐mg theanine
Number of subjects: 48
Study 17891480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both caffeine and theanine
Number of subjects: 48
Study 17891480 — intervention group
Group type: COMPARATOR
Intervention: Neither caffeine nor theanine (placebo)
Number of subjects: 48
Study 16025736 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine 4 mg
Number of subjects: 80
Study 16025736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12384193 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding status reported in RCTs
Number of subjects: 40
Study 12384193 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind RCTs
Number of subjects: 40
Study 12384193 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting practices of journals
Number of subjects: 40
Study 10591231 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit by an experienced occupational therapist for assessment and modification of environmental hazards
Number of subjects: 530
Study 10591231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 530
Study 8708496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral electrolyte solution made with rice syrup solids
Number of subjects: 0
Study 8708496 — intervention group
Group type: COMPARATOR
Intervention: Comparable glucose-based solution
Number of subjects: 0
Study 1874580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily - morning and 19h30
Number of subjects: 1745
Study 1874580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily - morning and 22h30
Number of subjects: 1745
Study 1874580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once daily at 19h30
Number of subjects: 1745
Study 1874580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once daily at 22h30
Number of subjects: 1745
Study 1874580 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 1745
Study 7089790 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic flow charts
Number of subjects: 0
Study 7089790 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient-centered teaching
Number of subjects: 0
Study 31306495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks)
Number of subjects: 60
Study 31306495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 60
Study 31306495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31141062 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded OAGB
Number of subjects: 20
Study 31141062 — intervention group
Group type: COMPARATOR
Intervention: Non-banded OAGB
Number of subjects: 20
Study 28774488 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (colloid)
Number of subjects: 91
Study 28774488 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution (crystalloid)
Number of subjects: 91
Study 26452996 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN-RSV01
Number of subjects: 87
Study 26452996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 25514451 — intervention group
Group type: COMPARATOR
Intervention: Extended Bandwidth (EBW) hearing aid processing
Number of subjects: 32
Study 25514451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Frequency Compression (NFC) hearing aid processing
Number of subjects: 32
Study 25514451 — intervention group
Group type: COMPARATOR
Intervention: Restricted Bandwidth (RBW) hearing aid processing
Number of subjects: 32
Study 25514451 — intervention group
Group type: EXPERIMENTAL
Intervention: Music processing
Number of subjects: 32
Study 20676755 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent aspirin use
Number of subjects: 2987
Study 20676755 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs2745559
Number of subjects: 2987
Study 20676755 — intervention group
Group type: EXPERIMENTAL
Intervention: Other SNPs
Number of subjects: 2987
Study 20629476 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden (FVL) testing
Number of subjects: 124
Study 20629476 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin G20210A testing
Number of subjects: 124
Study 20629476 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment
Number of subjects: 124
Study 20629476 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for FVL and prothrombin G20210A
Number of subjects: 124
Study 17462588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy methods focusing on childhood memories
Number of subjects: 21
Study 17462588 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy methods focusing on the present
Number of subjects: 21
Study 17462588 — intervention group
Group type: COMPARATOR
Intervention: Order of focus (past-present vs present-past)
Number of subjects: 21
Study 17462588 — intervention group
Group type: COMPARATOR
Intervention: Experience of the therapist with CT for personality disorders
Number of subjects: 21